Shares of Moderna Inc (NASDAQ: MRNA) rose in early trading on Monday, just days after the pharma company submitted an application to the Food and Drug Administration (FDA) for the
Kellogg Company (NYSE: K), which has consistently outperformed analyst forecasts during and after the pandemic, is gearing up to report its second-quarter earnings.